Physician profile
Justin Li
NPI 1689289977
$6,203.06
in general payments reported to CMS, 2019-2025
32 companies · $4,273 in 2025
The $4,273 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,930 · 2025: $4,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,203.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $929.52 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $848.73 | 2025 | |
| Lilly USA, LLC | $652.23 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Neurocrine Biosciences, INC. | $300.24 | 2024-2025 | Ingrezza |
| Amgen INC. | $285.94 | 2024-2025 | Krystexxa, Lumakras, Evenity |
| E.R. Squibb & Sons, L.L.C. | $277.69 | 2024-2025 | Reblozyl, Opdivo, Camzyos |
| Syndax Pharmaceuticals, INC. | $272.23 | 2025 | Revuforj |
| Pfizer INC. | $270.47 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $260.39 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $232.35 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $186.57 | 2024-2025 | Cresemba, Veozah |
| Corcept Therapeutics | $154.07 | 2025 | Korlym |
| Janssen Biotech, INC. | $133.87 | 2024 | Tremfya |
| Incyte Corporation | $122.90 | 2025 | Jakafi |
| Gilead Sciences, INC. | $121.93 | 2025 | Biktarvy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $121.86 | 2024 | Lunsumio, Polivy |
| Axsome Therapeutics, INC. | $121.72 | 2025 | Auvelity |
| Exact Sciences Corporation | $121.55 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Exelixis INC. | $120.89 | 2025 | Cabometyx |
| Mirati Therapeutics, INC. | $118.73 | 2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $113.08 | 2024 | Ultomiris |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $82.95 | 2024 | |
| Heartflow, INC. | $67.00 | 2025 | |
| Boston Scientific Corporation | $54.35 | 2024-2025 | Watchman Flx |
| Shield Therapeutics INC | $53.47 | 2024 | |
| Novartis Pharmaceuticals Corporation | $45.65 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.26 | 2024-2025 | Jardiance |
| Almatica Pharma LLC | $21.41 | 2025 | Loreev Xr |
| Radius Health, INC. | $20.53 | 2025 | Tymlos |
| Vertex Pharmaceuticals Incorporated | $18.72 | 2025 | |
| Glaxosmithkline, LLC. | $14.84 | 2025 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $13.92 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.